"Digoxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
| Descriptor ID |
D004077
|
| MeSH Number(s) |
D04.210.500.155.580.130.500.436 D04.210.500.155.580.130.688 D09.408.180.261.436
|
| Concept/Terms |
Digoxine Nativelle- Digoxine Nativelle
- Nativelle, Digoxine
- Hemigoxine Nativelle
- Nativelle, Hemigoxine
Lanoxin- Lanoxin
- Lanoxin-PG
- Lanoxin PG
- Lenoxin
|
Below are MeSH descriptors whose meaning is more general than "Digoxin".
Below are MeSH descriptors whose meaning is more specific than "Digoxin".
This graph shows the total number of publications written about "Digoxin" by people in this website by year, and whether "Digoxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Digoxin" by people in Profiles.
-
Closing the Digitalis Divide: Back to the Basics of Randomized Controlled Trials. Cardiovasc Drugs Ther. 2023 08; 37(4):807-813.
-
In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo. Ann Intern Med. 2021 06; 174(6):JC69.
-
Na+/K+-ATPase-Targeted Cytotoxicity of (+)-Digoxin and Several Semisynthetic Derivatives. J Nat Prod. 2020 03 27; 83(3):638-648.
-
Preventing enthusiasm in response to clinical advances. BJOG. 2019 06; 126(7):890.
-
Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma. Sci Transl Med. 2018 10 24; 10(464).
-
Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. Nat Commun. 2017 12 22; 8(1):2270.
-
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 2017 07 10; 32(1):71-87.e7.
-
Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. Sci Rep. 2016 07 19; 6:29721.
-
Digoxin Use Is Associated With Reduced Interstage Mortality in Patients With No History of Arrhythmia After Stage I Palliation for Single Ventricle Heart Disease. J Am Heart Assoc. 2016 Jan 11; 5(1).
-
A general strategy to construct small molecule biosensors in eukaryotes. Elife. 2015 Dec 29; 4.